Development of AVID200, a novel TGF-β targeting immunotherapy: characterization of immunomodulatory effects

From National Research Council Canada

DOIResolve DOI: http://doi.org/10.1016/S0959-8049(16)32910-0
AuthorSearch for: ; Search for: 1 ; Search for: 1 ; Search for: 1 ; Search for: 1 ; Search for: ; Search for: 1 ; Search for: 1 ; Search for: 1 ; Search for: 1 ; Search for: 1 ; Search for: ; Search for: 1 ; Search for: ; Search for:
Name affiliation
  1. National Research Council Canada. Human Health Therapeutics
TypeArticle
Journal titleEuropean Journal of Cancer
ISSN0959-8049
Volume69
PagesS105–
Abstract
In efficacy studies using the syngeneic 4T1 TNBC model, AVID200 was shown to promote significant T-cell infiltration into tumors. This infiltration resulted in reduced primary tumor growth as well as significant reductions in metastatic lesions. Additionally, ex vivo studies revealed that AVID200 treatment decreased T-cell apoptosis, promoted T-cell proliferation in response to tumor cell lysates in the presence of dendritic cells, as well as increased the capacity of T-cells to specifically lyse 4T1 tumor cells. The novel computational design of AVID200 results in a trap with low pM in vitro neutralization potency for TGF-b 1 and 3. Additionally, AVID200 markedly promotes the “T-cell-inflamed” tumor state in vivo. Combination studies with immune checkpoint inhibitors will be presented.
Publication date
Note28 EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics Wednesday 29 November 2016: Poster Sessions: Immunotherapy: Poster (Board P144)
LanguageEnglish
Peer reviewedYes
NPARC number23001208
Export citationExport as RIS
Report a correctionReport a correction
Record identifierfc21b4ce-4778-42e5-9a89-dade828fc71b
Record created2017-01-05
Record modified2017-01-05
Date modified:
Report a problem on this page